Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia

Lancet

Volumn 347, Issue 9013, 1996, Pages 1432-1438

  Johnson, Stephen ^a   Smith, Alastair G ^b   Löffler, Helmut ^c   Ösby, Eva ^d   Juliusson, Gunnar ^e   Emmerich, Berthold ^f   Wyld, Peter J ^g   Hiddemann, Wolfgang ^h  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^b ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF KIEL   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

^f UNIVERSITY OF MUNICH   (Germany)

^g Inveresk Clinical Research Ltd   (United Kingdom)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 15844368449     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(96)91681-5     Document Type: Article

References (30)

1. Turk W. Ein System der Lymphomatosen. Wien Klin Wochenschr 1903; 16: 1073-85.
2. Li FP. Epidemiology of chronic leukemias. In: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA, eds. Neoplastic diseases of the blood. New York: Churchill Livingstone, 1991: 7-14.
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34.
4. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
5. Dighiero G, Travade P, Chevret S, et al. B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991; 78: 1901-14.
6. Knospe WH, Loeb V, Hugulex CM. Biweekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 1974; 33: 555-62.
7. Montserrat E, Alcala A, Parody R, et al. Treatment of chronic lymphocytic leukemia in advanced stages: a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine and prednisone. Cancer 1985; 56: 2369-75.
8. French Cooperative Group on Chronic Lymphocytic Leukemia. Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986; i: 1346-49.
9. Hansen MM, Andersen E, Birgens H, et al. CHOP versus chlorambucil plus prednisolone in chronic lymphocytic leukemia. Leuk Lymph 1991; 5 (suppl): 97-100.
10. Kimby E, Mellstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type. A randomized trial. Leuk Lymph 1991; 5 (suppl): 93-96.
11. Spanish Cooperative Group PETHEMA. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (PETHEMA) trials. Leuk Lymph 1991; 5 (suppl): 89-91.
12. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-700.
13. Keating MJ, Kantarjian H, Talpaz M, et al. Fludabarine - a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
14. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia. Response predicted by rapid decrease of blood lymphocyte counts. J Clin Oncol 1993; 11: 679-89.
15. Elias L, Stock-Novack D, Head DR, et al. A phase I trial combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group Study. Leukemia 1993; 7: 361-65.
16. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4: 371-75.
17. Brochmann C, Schäger C, Grove D, et al. Immediate cytotoxity of fludarabine and potential induction of MDR expression in chronic lymphocytic leukemia. Ann Hematol 1993; 67 (suppl): 61.
18. Keating MJ, Hester JP, McCredie KB, et al. Long-term results of CAP therapy in chronic lymhocytic leukemia. Leuk Lymph 1990; 2: 391-97.
19. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia. Recommendations of the National Cancer Institute sponsored working group. Am J Hematol 1989; 29: 152-63.
20. Leporrier M, Reman O, Troussard X. Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia. Lancet 1993; 342: 555.
21. Binet JL, Chastang C, Chevret S, et al. Comparison of fludarabine (FDB), CAP and CHOP in advanced previously untreated chronic lymphocytic leukemia (CLL). Preliminary results of a randomized clinical trial. Blood 1993; 82 (suppl 1): 140a.
22. Rai KR, Peterson B, Kolitz J, et al. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). A randomised inter-group study. Blood 1905; 86 (suppl 1): 607a.
23. French Cooperative Group on CLL. Comparison of fludarabine (FDB), CAP and ChOP in previously untreated stage B and C chronic lymphocytic leukaemia (CLL). First interim results of a randomized clinical trial in 247 patients. Blood 1994; 83 (suppl 1): 461a.
24. Byrd JC, Hargis JB, Kester K, Hospenthal DR, Weidner S, Diehl L. Fludabarine therapy for lymphoid malignancies is associated with a high number of opportunistic pulmonary infections. Blood 1993; 82 (suppl 1): 538a.
25. Priebe T, Kandil O, Nakic M, Pan BF, Nelson JA. Selective modulation of antibody response and natural killer cell activity by purine nucleoside analogs. Cancer Res 1988; 48: 4799-803.
26. Priebe T, Ruiz L, Nelson JA. Adenosine receptors and modulation of natural killer cell activity by purine nucleosides and their analogs. Cell Immunol 1990; 130: 513-19.
27. Schäfer C, Brochmann C, Büchner Th, Hiddemann W, Wörmann B. In vivo effects of fludarabine on immunocompetent cells in patients with chronic lymphocytic leukemia and low grade non-Hodgkin lymphoma. Ann Hematol 1993; 67 (suppl): 412.
28. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Byron PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992; 3: 171-72.
29. Di Raimondo F, Giustolisi R, Cacciola E, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymph 1993; 11: 63-68.
30. Dighiero G. Potential immunological action of purine nucleoside analogues. Drugs 1994; 47(suppl 6): 57-62.